Taken together, these data suggest that the PI3K/PTEN/Akt/mTOR pathway may represent an important therapeutic target for HCC treatment in patients with differing etiologies that lead to the development of this aggressive tumor. The gene discussed is AKT1; the disease is hepatocellular carcinoma.